Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to ...

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw ...

SOTYKTU ® (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use: SOTYKTU is not ...

Rules being drafted by the Treasury Department would likely allow American drugmakers to invest in promising medicines being ...

Here's a revealing data point: older Americans are scared more of outliving wealth than of death itself. And unfortunately, even retirees who have built a nest egg have good reason to be ...

The other is that Anthropic will prioritise the interests of a subset of countries, defined either as the US and allies, or democracies, which have, respectively, only 17 per cent and 45 per cent of ...

All deal values reflect company disclosures. Where parties have not disclosed terms, they are reported as undisclosed. No ...

New evidence shows GLP-1s are safe and potentially life-extending for patients with complex psychiatric histories. Here is how to translate the research into clear, effective conversations.

A Brief History of Lyell Immunopharma◾️Lyell Immunopharma, founded by cell therapy expertsFounders and BackgroundLyell Immunopharma is a clinical-stage biopharmaceutical company founded in 2018 by ...

BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give ...

Patients with MS starting B-cell therapies had fewer relapses and less T2 lesion growth, but no measurable difference in disability after 2 years.